Telik, Inc. (Nasdaq: TELK) 16.2% HIGHER; announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10. Data on this study were presented at the 98th annual meeting of the American Association for Cancer Research on April 17, 2007.

Glimcher Realty Trust, (NYSE: GRT) 11.5% LOWER; announced that the agreement for the sale of its Lloyd Center property, a fully enclosed